

# Neurology RESEARCH REVIEW™

SUPPLEMENT:  
MULTIPLE SCLEROSIS

Making Education Easy

Issue 77 – 2021

## In this issue:

- Cumulative effects of therapies on disability in RRMS
- Prediction of MS outcomes when switching to ocrelizumab
- Rapid and sustained B cell depletion with subcutaneous ofatumumab in relapsing MS
- MENACTRIMS practice guideline for COVID-19 vaccination in pwMS
- Humoral and T-cell responses to COVID-19 vaccine in pwMS treated with ocrelizumab
- Association of DMT and anti-CD20 infusion timing with humoral response to SARS-CoV-2 vaccines
- Depression in MS
- Treatment escalation vs immediate initiation of highly effective treatment for RRMS
- Safety and efficacy of the oral BTK inhibitor tolebrutinib in relapsing MS
- Epilepsy as a predictor of disease progression in MS

### Abbreviations used in this issue

**BTK** = Bruton tyrosine kinase  
**COVID-19** = coronavirus disease 2019  
**DMT** = disease-modifying treatment  
**EDSS** = Expanded Disability Status Scale  
**MENACTRIMS** = Middle East North Africa Committee for Treatment and Research in MS  
**MRI** = magnetic resonance imaging  
**mRNA** = messenger ribonucleic acid  
**MS** = multiple sclerosis  
**pwMS** = people with MS  
**RRMS** = relapsing-remitting MS  
**SARS-CoV-2** = severe acute respiratory syndrome coronavirus 2  
**SPMS** = secondary progressive MS

Kindly supported by  
**NANZ - Neurological  
Society of New Zealand**



## Welcome to the latest issue of Neurology Research Review, focusing specifically on MS.

In this issue, a French cohort study finds that long-term use of DMT in RRMS delays the development of moderate disability and conversion to SPMS, an analysis of the MSBase Registry finds that the risk of disability worsening after switching to ocrelizumab is reduced by short treatment gaps, and the phase 2 APLIOS study of subcutaneous ofatumumab suggests we could be at beginning of a new and more convenient era for DMT. Also in this issue, we review a succinct summary of the current recommendations for COVID-19 vaccination in pwMS, and a dose-response study of the BTK inhibitor tolebrutinib in relapsing and progressive forms of MS provides rationale for further development of the drug.

We hope you find the selected studies interesting, and welcome your feedback.

Kind regards,

**Dr Jennifer Pereira**

[jenniferpereira@researchreview.co.nz](mailto:jenniferpereira@researchreview.co.nz)

## Cumulative effects of therapies on disability in relapsing multiple sclerosis

**Authors:** Rollet F et al.

**Summary:** This nationwide cohort study in France investigated the relationship between treatment exposure and disability risk in patients with RRMS. Associations between treatment duration and risk of disability were assessed using a novel weighted cumulative exposure model in 2285 adult patients (mean age 33.4 years, 75.0% female). The risk of disability decreased with increasing duration of exposure to DMTs. Compared to a 5-year treatment starting 10 years ago, a 15-year continuous treatment starting 20 years ago was associated with a 26% decrease in risk of irreversible EDSS 4, and a 34% decrease in risk of conversion to SPMS.

**Comment:** We know from randomised controlled trials in RRMS and their extension studies that immunotherapies reduce relapse rate and cumulative disease activity. These data provide additional evidence that the use of sustained long-term immunotherapy prevents cumulative disability and conversion to secondary progressive disease. This analysis was performed between 1996 and 2017 and the most frequently used DMTs were interferons (44.7%) and glatiramer acetate (11.9%) – low efficacy MS therapies, so the effects seen are likely to be greater in our current treated RRMS population. This study showed sustained treatment to be of greater benefit than early treatment. We aim for both early and sustained.

**Reference:** *Mult Scler* 2021;27(11):1760-70

[Abstract](#)

### Independent commentary by Dr Jennifer Pereira BHB, MBChB, FRACP, MD



After undergraduate training in medicine at the University of Auckland, Jennifer trained in neurology at Auckland City Hospital. Postgraduate training consisted of an MS research fellowship, with the Therapeutic Immunology Group in the Department of Clinical Neurosciences, University of Cambridge (UK). There she completed her MD focused on immunological changes after treatment of MS with alemtuzumab. Jennifer then returned to Auckland and works as consultant neurologist with a special interest in neuroimmunology in the Department of Neurology at Auckland City Hospital.



## Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Authors: Zhong M et al.

**Summary:** This analysis of MSBase Registry data evaluated predictors of relapse and disability progression in patients with RRMS when switching from another DMT to ocrelizumab. Prior DMTs included interferon-beta/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod and natalizumab. Multivariable Cox proportional hazard regression models showed that the risk of relapse was higher when switching from fingolimod compared with other DMTs, but only in the first 3 months of ocrelizumab therapy (hazard ratio [HR] 3.98, 95% CI 1.57–11.11;  $p=0.004$ ). The adjusted risk for 6-month confirmed disability progression increased with increasing washout duration (2–6 months vs <1 month: HR 9.57, 95% CI 1.92–47.64;  $p=0.006$ ).

**Comment:** We switch patients from fingolimod to ocrelizumab for a variety of reasons including breakthrough disease or complications of treatment such as macular oedema, low lymphocyte count or deranged liver function tests. The washout period between treatments cannot be standardised as the timing of ocrelizumab infusion may be impacted by the reason to switch. In this retrospective study, 14.3% of patients with a >2-month washout had a relapse during the washout and 9.9% had a relapse during the first year on ocrelizumab. The lowest risk of an on-ocrelizumab relapse when switching from fingolimod was when the washout was <1 month (2.8%). It appears from earlier studies quoted in this paper that ocrelizumab is able to deplete B cells sequestered in lymph nodes. The drug has a half-life of 26 days so it can target the repopulating peripheral lymphocytes as it happens (6–8 weeks after stopping treatment). If you are switching due to breakthrough disease you need to minimise the washout period – prospective data are still required.

Reference: *Mult Scler* 2021; published online Oct 8

[Abstract](#)

## Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis

Authors: Bar-Or A et al.

**Summary:** The phase 2 APLIOS study evaluated the bioequivalence of subcutaneous ofatumumab when administered by an autoinjector versus a prefilled syringe, and explored the effect of ofatumumab on B cell depletion. 256 patients with relapsing MS received subcutaneous ofatumumab 20mg every 4 weeks (after initial doses on days 1, 7, and 14). Patients were randomised 10:10:1:1 to receive an autoinjector or prefilled syringe dose in the abdomen, or an autoinjector or prefilled syringe dose in the thigh, respectively. The pharmacokinetics of abdominal ofatumumab were bioequivalent for the autoinjector versus prefilled syringe (geometric mean area under the curve, 487.7 vs 474.1  $h \times \mu\text{g/ml}$ ; maximum plasma concentration, 1.409 vs 1.409  $\mu\text{g/ml}$ ). Ofatumumab rapidly decreased B cell counts in all groups, from a median 214.0 cells/ $\mu\text{l}$  at baseline to 2.0 cells/ $\mu\text{l}$  on day 14.

**Comment:** Subcutaneous delivery of high efficacy MS treatments will save time, minimise hospital exposure in the COVID era and reduce the pressure on our busy infusion centres. Ofatumumab has been through phase 3 trials in this formulation and natalizumab has proven efficacy in phase 2 trials. Subcutaneous ocrelizumab trials are currently underway. It could be the beginning of a new and more convenient era!

Reference: *Mult Scler* 2021; published online Oct 4

[Abstract](#)

## MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis

Authors: Yamout Bl et al.

**Summary:** This practice guideline offers recommendations for vaccinating pwMS during the COVID-19 pandemic. A group of regional experts selected by MENACTRIMS reviewed the available evidence regarding COVID-19 vaccines in pwMS, and preliminary recommendations were developed by a subcommittee. They recommended that pwMS should be vaccinated against COVID-19 promptly. All COVID-19 vaccines are effective and do not appear to carry any additional risk for patients with MS. Once vaccinated, pwMS should continue to practise standard and recommended precautions against COVID-19. COVID-19 vaccines are safe to use in pwMS treated with DMTs, and there is no evidence that patients with MS are at higher risk for complications than the general population.

**Comment:** This paper offers a succinct summary of the current recommendation for COVID-19 vaccination in pwMS. It does not cover third vaccination which is available in NZ to individuals who are immunosuppressed. Third doses are advised between 8 weeks and 6 months after the second Pfizer vaccine dose and are indicated for pwMS on ocrelizumab and fingolimod.

Reference: *Mult Scler Relat Disord* 2021;56:103225

[Abstract](#)

CLICK HERE to read our

## Educational Series on Countering Vaccine Misinformation: A Practical Guide for Healthcare Providers

The article discusses vaccine misinformation and how it can undermine vaccine confidence and lead to vaccine hesitancy. Evidence-based strategies for countering vaccine hesitancy and misinformation are summarised. Techniques to support healthcare providers when engaging with individuals whose vaccine hesitancy has resulted from exposure to vaccine misinformation are provided.

**Authors:** Associate Professor Robin Fidoor-Bailey, Dr Amy Chan


**Keywords:** COVID-19, vaccine confidence, vaccine hesitancy, misinformation, healthcare providers

This article discusses vaccine misinformation and how it can undermine vaccine confidence and lead to vaccine hesitancy. Evidence-based strategies for countering vaccine hesitancy and misinformation are summarised. Techniques to support healthcare providers when engaging with individuals whose vaccine hesitancy has resulted from exposure to vaccine misinformation are provided.

RESEARCH REVIEW™  
Making Education Easy – Since 2006

Claim your CPD points for reading Research Reviews

FIND OUT MORE



**Tecfidera**  
(dimethyl fumarate)  
BECAUSE TOMORROW  
MATTERS TODAY

# TECFIDERA GIVES YOUR RRMS PATIENTS FLEXIBILITY IN FAMILY PLANNING<sup>1-3</sup>



## WHY CHOOSE TECFIDERA FOR WOMEN OF CHILDBEARING AGE?



TECFIDERA is the ONLY oral treatment for RRMS with an Australian Pregnancy Category B1<sup>1,4-7\*</sup>



No adverse pregnancy outcomes have emerged in over 9 years of clinical trial and real-world experience<sup>2,3,8</sup>



TECFIDERA can be used until conception<sup>1\*,†</sup>



TECFIDERA gives patients the freedom to choose their preferred contraceptive method, or to not use contraception at all<sup>1</sup>

Data from nonclinical (animal) studies do not suggest that TECFIDERA would be associated with an increased risk of teratogenicity or reduced fertility in either males or females.<sup>1,†</sup>

\*TECFIDERA should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus. No washout period required before conception. TECFIDERA is not contraindicated in pregnancy.<sup>1</sup> †TECFIDERA has a terminal half-life of ~1 hour, and no measurable metabolite is present at 24h in the majority of individuals.<sup>1</sup> †Animal data does not necessarily predict human clinical effect.



RRMS=relapsing-remitting multiple sclerosis.

**Reference:** 1. Tecfidera (dimethyl fumarate) Data Sheet, 5 March 2020. 2. Gold R *et al. Neurol Ther* 2015;4:93-104. 3. Hellwig K *et al. Poster presented at ACTRIMS-ECTRIMS: September 11-13 2020. Virtual conference.* 4. Gilenya (fingolimod) Data Sheet, 20 July 2020. 5. Aubagio (terifunomide) Data Sheet, 18 August 2020 / Aubagio (terifunomide) Product Information, 17 September 2020. 6. Fampyra (fampridine) Data Sheet, 31 January 2020. 7. Mavenclad (cladribine) Data Sheet, 11 May 2020 / Mavenclad (cladribine) Product Information, 15 January 2021. 8. Gold R *et al. Ther Adv Neurol Disord* 2020;13:1-17. 9. Desai A *et al. Eur J Pharm Med Res* 2016;3(5):197-205.

Before prescribing TECFIDERA please review the Data Sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

**TECFIDERA** (dimethyl fumarate [DMF]) 120 mg and 240 mg modified release capsules **INDICATIONS:** indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. **CONTRAINDICATIONS:** known hypersensitivity to DMF or any excipients in this product. **PRECAUTIONS:** Decreases in lymphocyte counts observed in patients treated in clinical trials were not associated with increased frequencies of infections. Due to the risk of serious, possibly fatal infection, patients who develop lymphopenia as a result of treatment, require close monitoring. Instruct patients to report symptoms of infection to their physician. For patients with signs and symptoms of serious infections, interrupting treatment should be considered until the infection(s) resolves. TECFIDERA may decrease lymphocyte counts. Prior to initiating treatment, a recent complete blood count (CBC) including lymphocytes (i.e. within 6 months) is recommended. A CBC, including lymphocytes, is also recommended after 6 months of treatment and every 6 to 12 months thereafter, and as clinically indicated. Consider interruption in patients with lymphocyte counts <0.5 x 10<sup>9</sup>/L persisting for more than 6 months. Lymphocyte counts should be followed until recovery. Assess benefit/risk in patients that experience moderate lymphopenia ≥6 months. Use caution in patients with pre-existing low lymphocyte counts. Progressive multifocal leukoencephalopathy (PML) has occurred in the setting of lymphopenia (<0.91 x 10<sup>9</sup>/L) in MS patients treated with Tecfidera. At the first sign or symptom suggestive of PML, withhold treatment and perform an appropriate diagnostic evaluation. Cases of anaphylaxis have also been reported. Patients should be instructed to discontinue and seek immediate medical care if they experience signs or symptoms of anaphylaxis and treatment should not be restarted. Serious cases of herpes zoster have occurred with TECFIDERA. Consider withholding TECFIDERA treatment in patients with serious infections until the infection has resolved. Patients taking TECFIDERA may receive non-live vaccines. Live vaccines are not recommended during treatment. Prior to initiating treatment, urinalysis should be available (within 6 months prior to starting therapy). During treatment, urinalysis is recommended annually and as clinically indicated. Use caution in patients who receive chronic medications associated with potential nephrotoxic risk. Pregnancy Category B1. Others: see full PI. **INTERACTIONS WITH OTHER MEDICINES:** TECFIDERA is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the TCA cycle, with no involvement of the CYP450 system. Simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided. **ADVERSE EFFECTS: Very common (>10%):** Flushing, diarrhoea, nausea, abdominal pain, abdominal pain upper. **Common (>1%):** gastroenteritis, lymphopenia, leucopenia, burning sensation, hot flush, vomiting, dyspepsia, gastritis, gastrointestinal disorder, pruritus, rash, erythema, proteinuria, feeling hot, albumin present in urine, aspartate aminotransferase and alanine aminotransferase increased and white blood cell count decreased. **Post-marketing:** PML has occurred in the setting of lymphopenia (<0.91 x 10<sup>9</sup>/L). Liver function abnormalities which resolved upon treatment discontinuation have been reported. LFTs monitoring is recommended as clinically indicated. Herpes zoster infection has been reported. Cases of anaphylaxis have also been reported. **DOSAGE AND ADMINISTRATION:** Starting dose is 120 mg b.i.d orally. After 7 days, increase to the recommended dose of 240 mg b.i.d orally. Do not crush, divide or dissolve the capsules or contents. Temporary dose reduction to 120 mg b.i.d may reduce flushing and GI side effects. Within 1 month, the 240 mg b.i.d dose should be resumed. Take with or without food. For patients who may experience GI or flushing side effects, taking TECFIDERA with food may improve tolerability. Administration of 325 mg non-enteric coated aspirin prior to dosing reduced the occurrence and severity of flushing in a study. **MEDICINES CLASSIFICATION:** Prescription Medicine. TECFIDERA capsules are supplied in blister packs: 14 for 120 mg and 56 for 240 mg. Store below 30°C. Store in original packaging to protect from light. **REVISION DATE - AUS:** February 2020; **NZL:** February 2020.

**NZ Mandatories:** TECFIDERA is a funded medicine – a prescription charge and Special Authority criteria will apply. Before prescribing please refer to the Data Sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz).

© Biogen and Tecfidera are registered trademarks of Biogen MA Inc. Biogen NZ Biopharma Ltd, 188 Quay Street, Auckland. ©2021 Biogen-975653. TAPS No. BG1035. TEC0160. Date of preparation: March 2021.



## Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab

**Authors:** Brill L et al.

**Summary:** This study in Israel investigated SARS-CoV-2 vaccine-specific humoral and cellular responses in pwMS treated with ocrelizumab. 49 pwMS treated with ocrelizumab, 40 healthy controls, and 23 untreated pwMS received 2 doses of the Pfizer/BioNTech (BNT162b2) COVID-19 vaccine between Dec 2020 and Apr 2021. Blood samples were taken 2–4 and 2–8 weeks after the second dose for antibody and T-cell assessments, respectively. 89.7% of patients treated with ocrelizumab and all of the healthy controls had SARS-CoV-2-specific T cells after vaccination (mean 15.4 and 14.3 spot-forming cells, respectively). Mean antibody titres and positive serology rates were lower in patients treated with ocrelizumab than in healthy controls and untreated patients, with a positive association with time from ocrelizumab infusion ( $p=0.04$ ).

**Comment:** Early data of seroconversion post COVID infection and COVID vaccination for pwMS on anti-CD20s has (not unsurprisingly) shown an attenuated B cell response. Early data show about 35% have no antibodies after the second dose of the Pfizer vaccine. To further understand the efficacy of the vaccine response for patients on these treatments, the analysis of the T cell response has been eagerly awaited. This study shows that the T cell response is equivalent to that of healthy controls. This is good news but it remains unknown how these laboratory data translate into real-world efficacy and protection against COVID infection.

**Reference:** *JAMA Neurol* 2021; published online Sep 23

[Abstract](#)

## Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis

**Authors:** Disanto G et al.

**Summary:** This observational cohort study investigated the humoral response to two COVID-19 mRNA vaccines in pwMS treated with DMTs. 120 pwMS (mean age 55 years; 61.7% women) from the Neurocentre of Southern Switzerland were included. Patients were receiving anti-CD20 therapies ( $n=58$ ), teriflunomide ( $n=24$ ), cladribine ( $n=15$ ), sphingosine-1-phosphate receptor (S1P) modulators ( $n=9$ ) and no therapy ( $n=14$ ). All participants received 2 SARS-CoV-2 mRNA vaccine doses and had serum samples collected within 2 weeks prior to the first vaccine dose and 21–35 days after the second dose to determine immunoglobulin G (IgG) production. All patients on teriflunomide or no therapy had appropriate humoral responses to SARS-CoV-2 vaccination, but 48.2% of those in the anti-CD20 group, 33.3% in the S1P modulator group, and 7.1% in the cladribine group remained seronegative 21–35 days after the second vaccine dose.

**Comment:** This study included 120 pwMS receiving the Moderna or Pfizer COVID-19 vaccine. Participants' serological response pre and 21–35 days post second vaccine dose was measured. 48% of those receiving anti-CD20 treatment and 33% of those in the S1P modulator group were seronegative after the second vaccine. In the anti-CD20 group there was a steady increase in the SARS-CoV2 IgG titre with time since last infusion. These data support earlier studies indicating that positive titres are more likely to occur 6 months after ocrelizumab and in proportion to the B cell count. If a robust B cell vaccine response is needed (rather than relying on the T cell response) to prevent serious COVID infection in individuals on these therapies, delaying ocrelizumab infusion may be the best strategy (with timing of vaccine guided by B cell repopulation), acknowledging the potential risk for MS-related relapse.

**Reference:** *JAMA Neurol* 2021; published online Sep 23

[Abstract](#)

## Depression in multiple sclerosis across the adult lifespan

**Authors:** Chan CK et al.

**Summary:** This analysis of MS PATHS data examined the burden of depressive symptoms across the adult age span in 13,821 pwMS compared with age-matched non-MS controls. The prevalence of depression was higher in pwMS than non-MS controls across the adult age span, but did not differ significantly between men and women across ages. Multivariable-adjusted regression models showed that the association between depression and processing speed (PST) or walking speed varied by age whereby depressed younger individuals had 0.45 standard deviation (SD; 95% CI  $-0.62, -0.29$ ) worse PST z-scores than non-depressed younger individuals, and older depressed individuals had 0.20 SD (95% CI  $-0.32, -0.08$ ) worse PST z-scores than non-depressed older individuals.

**Comment:** In this large study of 13,821 pwMS, the investigators examined the association between depression and measures of MS severity. Earlier studies estimated a lifetime prevalence of depression in pwMS of 50%. This study concluded that low mood can impact on physical and cognitive performance. 30% of pwMS in this study were being treated with an antidepressant and despite treatment 28% continued to report moderate to severe depression. Ask about symptoms of depression and response to current therapy for your patients – maximising treatment may not only improve mood but MS-related symptoms as well.

**Reference:** *Mult Scler* 2021;27(11):1771-80

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

[CLICK HERE](#)

to read previous issues of Neurology Research Review

## Physiotherapy Board of New Zealand

Reading Research Reviews can be included in registered Physiotherapists CPD plan and recorded as part of 100 hours of CPD over a three year period.

Please [CLICK HERE](#) to download CPD Information

Get your own copy of  
NEUROLOGY  
RESEARCH REVIEW

Become one of Research  
Review's 34,000 NZ members

[SIMPLY CLICK](#)

I am a Health Professional

to send us an e-mail and we'll do the rest

## Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis

**Authors:** Spelman T et al.

**Summary:** This cohort study used data from the Danish and Swedish national MS registries to investigate the impact of different DMT strategies for RRMS. 4861 pwMS who started treatment with DMT in 2013–2016 were followed up for a mean 4.1 years. 92.3% of the Danish patients initiated a low to moderately effective DMT (42.0% teriflunomide) and 7.6% initiated a highly effective DMT. In contrast, only 65.5% of Swedish patients initiated a low to moderately effective DMT (2.4% teriflunomide) and 34.5% initiated a highly effective DMT. Relative to the Danish treatment strategy, the Swedish strategy was associated with a 29% reduction in the rate of post-baseline 24-week confirmed disability worsening ( $p=0.004$ ), a 24% reduction in the rate of reaching EDSS 3 ( $p=0.03$ ), and a 25% reduction in the rate of reaching EDSS 4 ( $p=0.01$ ).

**Comment:** We are fortunate in NZ to be able to individualise treatment based on MS disease severity and factors such as pregnancy planning and patient choice. There are no head-to-head randomised controlled trials of moderate or high efficacy agents. There is, however, increasing evidence from observational studies that using high efficacy therapy early leads to better MS-related disability outcomes. This cohort study analysing nationwide registry data shows that the clinical practice in Sweden (using high efficacy rituximab or natalizumab as first line, or early escalation to a high efficacy agent) led to better treatment outcomes than the Danish approach (teriflunomide as first line with a tendency to switch to a still moderate efficacy agent, fingolimod, for breakthrough disease).

**Reference:** *JAMA Neurol* 2021;78(10):1197-1204

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

## Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis

**Authors:** Reich DS et al.

**Summary:** This phase 2b study determined the dose-response relationship between oral tolebrutinib and the reduction in new active brain MRI lesions in patients with relapsing MS. At 40 centres in 10 countries in Europe and North America, 130 patients aged 18–55 years with relapsing MS (either RRMS or SPMS) were randomised to receive tolebrutinib 5, 15, 30, or 60mg once daily, or placebo. MRI scans were performed at screening and every 4 weeks thereafter. At treatment week 12, there was a significant dose-dependent reduction in the mean number of new gadolinium-enhancing lesions in tolebrutinib recipients (1.39, 0.77, 0.76 and 0.13 with tolebrutinib 5, 15, 30, and 60mg, respectively), compared with placebo recipients (1.03). Headache was the most common non-serious adverse event reported with tolebrutinib, and no safety-related discontinuations or treatment-related deaths occurred.

**Comment:** The BTK enzyme plays a key role in B cell receptor signalling that regulates B cell proliferation, maturation, antigen presentation, and immunoglobulin production. BTK is not only expressed in B cells but also innate immune cells such as the microglia that reside in the CNS and contribute to the “smouldering plaque”. It is hoped that these agents (at least 4 under development) will work similarly to the anti-CD20s but without the cellular depletion and with the added bonus of penetrating the CNS, acting locally to reduce inflammation in chronically active lesions. A phase 3 trial of tolebrutinib versus 14mg of teriflunomide for the treatment of RRMS is underway, as are 2 other studies evaluating this medication for the treatment of primary progressive MS and SPMS.

**Reference:** *Lancet Neurol* 2021;20(9):729-38

[Abstract](#)

## Epilepsy as a predictor of disease progression in multiple sclerosis

**Authors:** Grothe M et al.

**Summary:** This case-control study used data from the German MS register to examine whether epilepsy in MS leads to increasing disability over time. Analysis of data for 31,052 pwMS showed that secondary progressive disease course, age, and disability were associated with the 5-year prevalence of epilepsy. Patients who developed epilepsy during the course of the disease had a higher EDSS score at disease onset (2.0 vs 1.5), higher disability at final 15-year follow-up (EDSS 4.4 vs 3.4) and lower employment status (40% vs 65%) than matched control patients.

**Comment:** MRI studies have found that more extensive MS cortical pathology correlates with higher levels of disability and an increased risk of seizures. This case-control study analysed disability levels over time in patients with MS who also had epilepsy – EDSS scores were analysed over 15 years. Interestingly, those with epilepsy had higher EDSS scores after the first year of diagnosis, and as expected more rapid progression and increased disability over the course of the study. In a sub-cohort, the authors found time from disease onset to first treatment and exposure time to a DMT did not alter epilepsy prevalence. This is disappointing but fits with our understanding that cortical MS pathology is neurodegenerative or due to meningeal-related lymphoid aggregates, neither of which are treatable with our current immunotherapies.

**Reference:** *Mult Scler* 2021; published online Oct 1

[Abstract](#)

**RACP MyCPD Program participants** can claim **one credit per hour** (maximum of 60 credits per year in Category One – Educational Activities) for reading and evaluating Research Reviews.

Please [CLICK HERE](#) to download CPD Information

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.